Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report released on Sunday. The firm issued a hold rating on the stock.

A number of other research analysts also recently commented on ONCT. Northland Capmk downgraded shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. HC Wainwright cut their price objective on Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Brookline Capital Management reiterated a “hold” rating on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Finally, Northland Securities reiterated a “market perform” rating and issued a $2.00 price target on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $20.00.

Oncternal Therapeutics Stock Performance

Shares of NASDAQ ONCT opened at $1.62 on Friday. Oncternal Therapeutics has a 1 year low of $1.05 and a 1 year high of $13.14. The stock’s 50-day simple moving average is $2.08 and its 200-day simple moving average is $5.57. The firm has a market cap of $4.80 million, a price-to-earnings ratio of -0.13 and a beta of 1.33.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($2.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.03) by $0.14. The company had revenue of $0.80 million for the quarter, compared to the consensus estimate of $0.24 million. Oncternal Therapeutics had a negative return on equity of 136.10% and a negative net margin of 1,948.70%. During the same period in the previous year, the business earned ($3.00) EPS. As a group, research analysts predict that Oncternal Therapeutics will post -12.43 EPS for the current year.

Institutional Trading of Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC acquired a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned approximately 0.84% of Oncternal Therapeutics as of its most recent SEC filing. 16.05% of the stock is currently owned by institutional investors and hedge funds.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.